Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients with Necrotic High-risk Coronary Plaque Disease - DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury

niversity of Edinburgh0 个研究点目标入组 202 人开始时间: 2014年7月4日最近更新: 2019年2月28日

适应症

试验速览

暂无简介。

•1) Patients aged =40 years with angiographically proven multivessel coronary artery disease defined as at least two major epicardial vessels with any combination of either (a) >50% luminal stenosis, or (b) previous revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery).
•2) Provision of informed consent prior to any study specific procedures
•3) Receiving aspirin
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 150

•1.An acute coronary syndrome within the last 12 months
•2.An indication for dual anti-platelet therapy, such as drug eluting stent
•3.Receiving thienopyridine therapy such as clopidogrel or prasugrel
•4.Percutaneous coronary intervention or coronary artery bypass graft surgery within the last 3 months
•5.Inability or unwilling to give informed consent
•6.Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial
•7.Known hypersensitivity to ticagrelor or one of its excipients
•8.Active pathological bleeding or bleeding diathesis
•9.Significant thrombocytopenia: platelets <100 x 109 /L
•10. History of intracranial haemorrhage
•11.Moderate to severe liver impairment (Child’s Grade B or C)
•12.Maintenance therapy with strong CYP3A4 inhibitors, such as ketoconazole, nefazodone, ritonavir, indinavir, atazanavir, or clarithromycin
•13.Major intercurrent illness or life expectancy <1 year
•14.Renal dysfunction (eGFR =30 mL/min/1.73 m2)
•15.Contraindication to iodinated contrast agents
•16.Planned coronary revascularization or major non-cardiac surgery in the next 12 months
•17. Maintenance therapy with simvastatin or lovastatin at doses greater than 40mg daily
•18.Receiving oral anticoagulants including warfarin, rivaroxaban, dabigatran or apixaban.

发起方

niversity of Edinburgh